Pancreatic Neuroendocrine Tumor - 25 Studies Found

Active, not recruiting : Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
: Gastroenteropancreatic Neuroendocrine Tumors
: 2014-09-02
:
  • Drug: Lanreotide Autogel 120 mg

Completed : 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
: Gastroenteropancreatic Neuroendocrine Tumors
: 2014-06-03
: Drug: 68Ga-OPS202
Completed : 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs
: Gastroenteropancreatic Neuroendocrine Tumors
: 2013-04-25
: Drug: Intravenous injection of 177Lu-octreotate Treatment will consist of 177Lu-octreotate injections in
Completed : Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
: Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
: 2010-12-16
:
  • Drug: Pasireotide LAR followed by Pasireotide LAR + Everolimus
Not yet recruiting : TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors
:
  • Neuroendocrine Tumors
  • Neuroendocrine Carcinoma
  • Temozolomid
    : 2017-03-09
    : Drug: TEMCAP Oral capecitabine 750 mg/m2 twice a day, Day 1 to 14 and oral temozolomide 200 mg/m2 once a
Completed : Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
:
  • Gastroenteropancreatic Neuroendocrine Tumor
  • Lung Neuroendocrine
    : 2016-10-27
    : Procedure: NETest 5 mL of blood will be drawn from participants for testing.
Active, not recruiting : The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases
:
  • Gastro-enteropancreatic Neuroendocrine Tumor
  • Secondary Malignan
    : 2011-08-24
    : Other: magnetic resonance imaging (MRI) Each patient will
Active, not recruiting : RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
: Pancreatic Neuroendocrine Tumor
: 2007-12-17
:
  • Drug: RAD001 Given orally once
Completed : Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
: Pancreatic Neuroendocrine Tumors
: 2010-05-10
: Drug: Sunitinib Sunitinib capsule will be given orally at continuous daily dosing with a dose of 37.5 mg
Active, not recruiting : A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
: Well-differentiated Pancreatic Neuroendocrine Tumor
: 2012-01-13
: Drug: sunitinib Sunitinib capsules will be given orally at continuous daily dosing with a starting dose
<<< Previous | Next >>>